Navigation Links
Sysmex America Receives FDA Clearance for XE-5000(TM) Hematology Analyzer
Date:12/11/2007

MUNDELEIN, Ill., Dec. 11 /PRNewswire/ -- Sysmex America, Inc. today announced that its Sysmex XE-5000 Automated Hematology Analyzer has been cleared by the United States Food and Drug Administration (FDA) for sale in the U.S. The XE-5000 represents an enhanced, best-in-class, high throughput analyzer that provides 31 whole blood reportable parameters including advanced clinical parameters and a body fluid specific mode. The Sysmex XE-5000 will be available in the United States, in Latin America and in Canada beginning in December 2007.

Like its other X-Series counterparts, the XE-5000 uses Sysmex's patented fluorescent flow cytometry technology, providing both routine hematology testing and abnormal cell flagging within a single sample run. The body fluid specific mode is the first of its kind in the industry with reportable body fluid differential parameters for all common body fluids (CSF, Serous and Synovial). Complete information within a single analysis reduces manual intervention and the errors inherent in manual counts. Hospital or university laboratories and clinics with renal, oncology and acute care patient populations will benefit from the XE-5000.

"The XE-5000 is Sysmex's next step in aiding our nation's larger-volume clinical laboratories in their efforts to become increasingly efficient with their staffing and financial resources without sacrificing quality or accuracy. With the proven reliability of Sysmex analyzers, clinical laboratories have the assurance of greater uptime," said John Kershaw, president, Sysmex America, Inc.

As with other Sysmex product lines, the XE-5000's performance can be remotely monitored by SNCS(TM) (Sysmex Network Communications Systems). SNCS continuously collects and monitors hundreds of real-time performance codes from Sysmex analyzers. This feature generates a technical review of any potential critical instrument errors that may be occurring behind the scenes. The connectivity allows Sysmex technicians to proactively contact the customer and to help correct any issues prior to system or part failures.

Sysmex hematology analyzers have been ranked as the industry's best in reliability and performance for eight consecutive years by the IMV ServiceTrak(TM) survey. IMV ServiceTrak(TM), conducted by an independent research company that analyzes science-based instrument industries, surveyed more than 1,600 randomly chosen clinical laboratory health care professionals from varying hospital sizes across the country.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems. Serving customers for over 35 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide. For more information about Sysmex, please visit http://www.sysmex.com/usa.


'/>"/>
SOURCE Sysmex America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sysmex America Awarded Hematology Contract by Amerinet
2. Many Older Americans Have Active Sex Lives
3. Despite grumbling, most Americans say they are happy at work
4. Record Number of Americans Lack Health Insurance
5. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
6. Campaign for Americas Future Memorandum: Katrina Storm Warning
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
9. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
10. Novo Nordisk Appoints New Leader of North American Business
11. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology: